Tower Research Capital LLC (Trc) Tempest Therapeutics, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $4.87 Billion
- Q4 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Tempest Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 10,918 shares of TPST stock, worth $10,153. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,918
Previous 6,033
80.97%
Holding current value
$10,153
Previous $8,000
12.5%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding TPST
# of Institutions
37Shares Held
5.74MCall Options Held
27.9KPut Options Held
139K-
Versant Venture Management, LLC San Francisco, CA3.51MShares$3.26 Million4.35% of portfolio
-
Black Rock Inc. New York, NY550KShares$511,7240.0% of portfolio
-
Jane Street Group, LLC New York, NY493KShares$458,5770.0% of portfolio
-
Geode Capital Management, LLC Boston, MA354KShares$329,4760.0% of portfolio
-
Ubs Group Ag196KShares$181,9780.0% of portfolio
About Tempest Therapeutics, Inc.
- Ticker TPST
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 10,418,900
- Market Cap $9.69M
- Description
- Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxiso...